Identification of three NFAT binding motifs in the 5′-upstream region of the human CD3γ gene that differentially bind NFATc1, NFATc2, and NF-κB p50

被引:35
作者
Badran, BM
Wolinsky, SM
Burny, A
Willard-Gallo, KE
机构
[1] Univ Brussels, Fac Med, Lab Expt Hematol, B-1000 Brussels, Belgium
[2] Northwestern Univ, Sch Med, Dept Med, Div Infect Dis, Chicago, IL 60611 USA
关键词
D O I
10.1074/jbc.M206330200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human immunodeficiency virus, type 1 (HIV-1) infection of CD4(+) T cells progressively abrogates T cell receptor (TCR)-CD3 function and surface expression by specifically interfering with CD3gamma gene transcription. Our data show that the loss of CD3gamma transcripts begins very early after infection and accumulates to a >90% deficiency before a significant effect on surface receptor density is apparent. Blocking TCR-CD3-directed NFAT activation with cyclosporin A provokes a partial re-expression of CD3gamma gene transcripts and surface complexes in a time- and dose-dependent manner. We have identified three NFAT consensus sequences (5'-GGAAA-3') in the 5'-upstream region of the human CD3gamma gene at: -124 to -120 (NFAT(gamma1)), -384 to -380 (NFAT(gamma2)), and +450 to +454 (NFAT(gamma3)) from the first transcription initiation site. Using electrophoretic mobility shift and supershift assays, we show that NFATc2 alone binds to the NFAT(gamma2) motif, however, complexes containing either NFATc2 or NFATc1 plus NF-kappaB p50 bind to the NFAT(gamma1) and NFAT(gamma3) sites. We further demonstrate that NFATc1 and NF-kappaB p50 bind in the same protein-DNA complex and that a fourth Ala added to the core sequence (5'-GGAAA (A) under bar -3') in NFAT(gamma1), and NFAT(gamma3) is critical for their binding. Finally, we have shown that an increase in the binding of nuclear NFATc2, NFATc1, and NF-kappaB p50 to these three motifs is correlated with a progressive loss of CD3gamma transcripts after HIV-1 infection.
引用
收藏
页码:47136 / 47148
页数:13
相关论文
共 97 条
[61]   TRANSCRIPTIONAL REGULATION OF THE T-CELL ANTIGEN RECEPTOR ZETA-SUBUNIT - IDENTIFICATION OF A TISSUE-RESTRICTED PROMOTER [J].
RELLAHAN, BL ;
JENSEN, JP ;
WEISSMAN, AM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1529-1534
[62]  
Rothwarf D.M., 1999, SCI STKE, V1999, pRE1
[63]   Some hints concerning the shape of T-cell receptor structures [J].
Rubin, B ;
Alibaud, L ;
Huchenq-Champagne, A ;
Arnaud, J ;
Toribio, ML ;
Constans, J .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (02) :111-118
[64]   The T-cell receptor ζ chain contains two homologous domains with which simian immunodeficiency virus Nef interacts and mediates down-modulation [J].
Schaefer, TM ;
Bell, I ;
Fallert, BA ;
Reinhart, TA .
JOURNAL OF VIROLOGY, 2000, 74 (07) :3273-3283
[65]   INDUCIBLE NUCLEAR FACTOR BINDING TO THE KAPPA-B-ELEMENTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS ENHANCER IN T-CELLS CAN BE BLOCKED BY CYCLOSPORINE-A IN A SIGNAL-DEPENDENT MANNER [J].
SCHMIDT, A ;
HENNIGHAUSEN, L ;
SIEBENLIST, U .
JOURNAL OF VIROLOGY, 1990, 64 (08) :4037-4041
[66]   Human immunodeficiency virus type 2 produces a defect in CD3-γ gene transcripts similar to that observed for human immunodeficiency virus type 1 [J].
Segura, I ;
Delmelle-Wibaut, C ;
Janssens, M ;
Cleuter, Y ;
Van den Broeke, A ;
Kettmann, R ;
Willard-Gallo, KE .
JOURNAL OF VIROLOGY, 1999, 73 (06) :5207-5213
[67]   MOLECULAR CHARACTERIZATION OF HUMAN T-CELL LEUKEMIA (LYMPHOTROPIC) VIRUS TYPE-III IN THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME [J].
SHAW, GM ;
HAHN, BH ;
ARYA, SK ;
GROOPMAN, JE ;
GALLO, RC ;
WONGSTAAL, F .
SCIENCE, 1984, 226 (4679) :1165-1171
[68]   Interaction of NF-kappa B and NFAT with the interferon-gamma promoter [J].
Sica, A ;
Dorman, L ;
Viggiano, V ;
Cippitelli, M ;
Ghosh, P ;
Rice, N ;
Young, HA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (48) :30412-30420
[69]   HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression [J].
Stefanova, I ;
Saville, MW ;
Peters, C ;
Cleghorn, FR ;
Schwartz, D ;
Venzon, DJ ;
Weinhold, KJ ;
Jack, N ;
Bartholomew, C ;
Blattner, WA ;
Yarchoan, R ;
Bolen, JB ;
Horak, ID .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (06) :1290-1297
[70]  
SUZUSHIMA H, 1991, CANCER RES, V51, P6084